Gandhar Oil Refinery (India) Q3 FY25 consolidated revenues reaches Rs. 1,005.3 Cr
Consolidated manufacturing volumes for Q3 FY25 remained stable at 132,187 KL, while for 9M FY25 it stood at 372,505 KL
Consolidated manufacturing volumes for Q3 FY25 remained stable at 132,187 KL, while for 9M FY25 it stood at 372,505 KL
Sanofi would not manufacture or market any product which infringes the amended claims of Panacea patent, IN272351
The new bioeconomy policy rolled out by the Modi government is set to place India as a global leader in the years to come
The robotic surgery program has continually pushed the boundaries of medical technology
Research & Development (R&D) investments for the quarter stood at Rs. 392.5 crore which is 6.3% of its revenues
Offering testing, treatment and support to help stop the spread of HIV and other infectious diseases
Vivity is the first and only wavefront-shaping IOL with Alcon’s proprietary X-WAVE Technology
Cipla will be responsible for the distribution of Sanofi India's six CNS brands including Frisium
The launch of Elores in Ecuador is expected to open the doors for the entry of the novel antibiotic adjuvant entity in other important Latin American countries
Subscribe To Our Newsletter & Stay Updated